research 851 The role of astrotactin2 in regulating mammalian skin polarity
Astrotactin2 affects hair follicle orientation and skin cell polarity.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Striking poses: The fantastic figure of Yul Brynner
Yul Brynner's unique physical presence and gestures defined his star image.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Hair growth-promoting effect of Aconiti Ciliare Tuber extract mediated by the activation of Wnt/β-catenin signaling
Aconiti Ciliare Tuber extract may help hair grow by activating a specific cell signaling pathway.
research Angiopoietin-1 induces survival and proliferation of hair follicle dermal papilla cells through integrin α5β1 signaling
Angiopoietin-1 helps hair cells survive and grow, making it a potential treatment for hair loss.
research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research 1370 MTORC1 activity is increased in the skin of acne patients and is suppressed with isotretinoin treatment
Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.
research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
research The T-cell antigen receptor: paradigm recalled
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Conditional Activin Receptor Type 1B (Acvr1b) Knockout Mice Reveal Hair Loss Abnormality
Disrupting Acvr1b in mice causes severe hair loss and thicker skin.
research ADVERTISING AND FICTION IN THE PICKWICK PAPERS
The conclusion is that advertising is a key part of "The Pickwick Papers," reflecting the consumer culture of Victorian Britain.
research Protective Effect of Retinoic acid preconditioning on H2O2-induced Apoptosis in Hair Cell-like Cells
Retinoic acid reduces cell damage from oxidative stress.
research A Receptor-Like Kinase Mediates Ammonium Homeostasis and Is Important for the Polar Growth of Root Hairs inArabidopsis
The CAP1 gene helps control ammonium levels and is necessary for the proper growth of root hairs in Arabidopsis.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
This case report highlights the successful use of upadacitinib, a selective JAK1 inhibitor, in treating a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata, conditions that share the JAK-STAT signaling pathway. Conventional therapies had failed, but upadacitinib (15 mg daily) led to rapid improvement: pruritus subsided within days, AD-related erythema cleared by 15 weeks, complete eyebrow regrowth occurred within months, and significant vitiligo repigmentation was observed at one year. The treatment was well-tolerated, suggesting that upadacitinib monotherapy could be an effective and well-tolerated option for these co-existing conditions, supporting a "multi-disease therapy" approach targeting common pathogenic pathways.
research UVA-1 in the treatment of alopecia areata
UVA-1 phototherapy might help treat alopecia areata.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
The study conducted a cost-per-responder analysis comparing ritlecitinib and baricitinib for treating severe alopecia areata. Ritlecitinib, a JAK3/TEC inhibitor, showed greater efficacy and a lower cost per responder than baricitinib, a JAK1/2 inhibitor, at both Weeks 24 and 52. Specifically, 52.10% of ritlecitinib initiators achieved a significant response by Week 24 compared to 36.28% for baricitinib. By Week 52, 40.26% of ritlecitinib users reached the desired outcome versus 30.63% for baricitinib. The cost per responder was lower for ritlecitinib at both time points, suggesting it may be a more cost-effective option for inclusion in treatment plans for severe alopecia areata.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research 115 AE法による実機水車発電機軸受の診断(セッション4 評価・診断II)
KSR1 is crucial for certain skin tumor formation and could be a cancer therapy target.
research The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin‐1 (PN‐1) inhibition
CAP1/Prss8 does not activate PAR2 or inhibit PN-1.
research Role of the ACTH/MC2R System in the Hair Cycle in Mice
The ACTH/MC2R system is crucial for controlling hair growth cycles in mice.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research DEEP REINFORCEMENT LEARNING FOR SCALABLE CONTROL OF BOOLEAN MODELS IN THE CONTEXT OF CELLULAR REPROGRAMMING
pbn-STAC effectively finds strategies for cellular reprogramming using deep reinforcement learning.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.